PatientsVille.com Logo

FLUSHING and Atenolol

PatientsVille

FLUSHING Symptoms and Causes

Normally, your cells grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy is drug therapy for cancer. It works by killing the cancer cells, stopping them from spreading, or slowing their growth. However, it can also harm healthy cells, which causes side effects.

You may have a lot of side effects, some, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts. Some common side effects are fatigue, nausea, vomiting, pain, and hair loss. There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.

Your treatment plan will depend on the cancer type, the chemotherapy drugs used, the treatment goal, and how your body responds. Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells. You might take the drugs by mouth, in a shot, as a cream, or intravenously (by IV).

NIH: National Cancer Institute

Check out the latest treatments for FLUSHING

FLUSHING treatment research studies

Atenolol clinical trials, surveys and public health registries


Find Drug Side Effect reports



Atenolol Side Effects

Bradycardia (333)
Dizziness (236)
Hypotension (218)
Completed Suicide (205)
Dyspnoea (180)
Nausea (171)
Blood Pressure Increased (150)
Syncope (145)
Hypertension (141)
Asthenia (141)
Fatigue (124)
Diarrhoea (124)
Headache (118)
Pain (115)
Malaise (110)
Toxicity To Various Agents (108)
Chest Pain (107)
Fall (98)
Palpitations (93)
Cerebrovascular Accident (89)
Vomiting (87)
Insomnia (81)
Myocardial Infarction (79)
Anxiety (78)
Oedema Peripheral (76)
Off Label Use (75)
Depression (75)
Pruritus (74)
Feeling Abnormal (73)
Back Pain (69)
Pain In Extremity (67)
Renal Failure Acute (66)
Abdominal Pain (66)
Arthralgia (66)
Weight Decreased (63)
Cough (62)
Heart Rate Increased (58)
Muscle Spasms (58)
Rash (58)
Blood Creatinine Increased (57)
Pneumonia (54)
Hyperkalaemia (54)
Loss Of Consciousness (53)
Overdose (53)
Weight Increased (53)
Hyperhidrosis (52)
Blood Cholesterol Increased (51)
Heart Rate Decreased (50)
Renal Failure (50)
Somnolence (50)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

8-)Have been taking atenolol and lisinipril for about 6 years, and before now did not realize the extreme itchiness in toes and fingers that started at first and now has turned in very cold and numb toes and feet and getting worse. I now believe it

Anxiety, Paranoia, Arrythmia

Before I took atenolol i had a perfect glucose numbers after taking it I came down with diabetes. I am 102lbs, 4'11, have always eaten healthy, exercise my whole life. I am 76. I was taken off atenolol after5 years...and NO ONE in my family for ge

Buenas quisiera saber si venden el medicamento rapamude o sirolimus en jarabe de 120 ml quisiera saber el costo,espero pronta respuesta muchas gracias

Congested chest

Has anyone else suffered from Atenelol induced Asthama and Bronchitis?

I have certain days of fatigue and I have constant chest congestion. How much can be attributed to the Atenolol or to my medical condition (atrial fibrulation)--I do not know.

I was started on atenolol for anxiety to stop the adrenilin, my bp was just a little elevated 150-100 during paniac attack. Will this drug work for anxiety?

I was told by increasing Atenol to 100 mg the pos. side effect was it protected your eyes from diabetes is this true on Your Mind?

It is the worst drug ever made made meel feel like been run over

After the first treatment I had some eye dryness and flushing both of which were not bad. After the second treatment I have very dry eyes and blured vision. The flushing with the second treatment has been unbearable. I h

Do Not Take This Medication. I am a physician who had surgery and prescribed for post op pain. Horrible Side Effects.Horrible Dizziness, Rash, Flushing, which lasted an extended period of time. I will not prescribe this medication to a patient and

Facial flushing and heaviness of the eyes

Flushing chest pain itchy joint pain sleeplessness memory loss short term mood swings depression

Flushing of cheeks, neck area after taking 50mg for pain associated with breast reconstruction

Horrible antibiotic taste in my mouth!! Its like the antibiotics have not down / having a reflux. Flushing down with water to lessen bitter pill taste in my mouth , not really helpingHave h-pylori and on 7 day course. Can't wait to finish this awfu

I am currently involve in a case study about hypercholesterilemia, our patient was given Niacin and Cholestyramine resin(Questran) it was stop because the patient cannot tolerate the flushing and gastrointestinal effects bought by this drugs and repl

I forgot to mention - my blood pressure during this mornings' flushing/SVT episode was 180/112. This morning before I took the Sular (with 12.5mg lopressor) it was 128/88. I almost didnt take the Sular but decided not to treat myself then ask the d

I have been taking Requip for at least 5-6 yrs now for RLS.Biggest mistake I ever made.Every time I try to stop it it is horrible!I have severe flushing of my face,my BP gets high,nauseated, my RLS gets worse,can't sleep etcThe emotional turmoill i

Remicade treatments in 2003 for Crohn's disease. During administration of my third dose, I immediately experienced severe chest pain, flushing, increased heart rate, and vomitting. In 2004, an abdominal CT was clear. In 2007, I was diagnosed with n

FLUSHING Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.
Condition: Chronic Stable Angina
Interventions: Drug: Nicorandil;   Drug: Atenolol
Outcome Measures: SPECT Tc99m- Tetrofosmin (MYOVIEW);   Exercise ECG Testing - Bruce protocol
2 Recruiting Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol
Condition: Marfan Syndrome
Interventions: Drug: Aliskiren;   Drug: Atenolol
Outcome Measures: Central aortic PWV(pulsed wave velocity);   Central aortic distensibility by MRI at week 24
3 Recruiting A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function
Condition: Hypertension
Interventions: Drug: Nebivolol;   Drug: Atenolol;   Drug: placebo
Outcome Measures: Comparing effects of nebivolol against Atenolol and placebo on endothelial function;   Evaluate effects of nebivolol as compared to Atenolol and placebo
4 Recruiting Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
Condition: Atrial Fibrillation
Intervention: Drug: Atenolol
Outcome Measure: Ventricular rate response during exercise.
5 Recruiting Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients
Condition: Hypertension
Interventions: Drug: Fimasartan;   Drug: Atenolol
Outcome Measures: The difference of sitting Systolic Blood Pressure(SiSBP) between at the peak compared to at resting;   The difference of sitting Diastolic Blood Pressure(SiDBP) at the peak compared to at resting;   The difference of sitting Systolic Blood Pressure(SiSBP) at each exercising stage compared to at resting;   The difference of sitting Systolic Blood Pressure(SiSBP) among at resting, each exercising stage and recovery
6 Recruiting Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol
Conditions: Hypertension;   Metabolic Syndrome
Interventions: Drug: Atenolol;   Drug: Bisoprolol
Outcome Measures: central blood pressure;   peripheral resistance;   cardiac index;   pulse wave velocity
7 Recruiting Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)
Condition: Cardiac Disease
Interventions: Drug: Atenolol;   Drug: Telmisartan
Outcome Measures: Change from baseline in ascending aorta size, as evaluated by MRI;   Rate of change in ascending aorta size evaluated by transthoracic echocardiography (TEE).
8 Unknown  Examining Genetic Influence on Response to Beta-Blocker Medications in People With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: Atenolol
Outcome Measures: Change in diastolic function (annular tissue velocity [Em]);   Change in free fatty acid kinetics;   Change in insulin sensitivity, glucose effectiveness, glucose, insulin, high-density lipoprotein (HDL), or triglycerides
9 Unknown  A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome
Condition: Marfan Syndrome
Interventions: Drug: Losartan and Atenolol or Propranolol;   Drug: Atenolol or Propranolol
Outcome Measure: Echocardiograms
10 Recruiting Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones
Condition: Healthy
Interventions: Drug: Saline;   Drug: Glucagon;   Drug: Placebo;   Drug: Atenolol
Outcome Measures: Circulating acyl-ghrelin concentration after glucagon stimulation with and without beta-adrenergic blockade;   Association between circulating acyl-ghrelin concentration and GH and cortisol after glucagon administration with and without beta-adrenergic blockade
11 Recruiting Genetic Mechanisms in Human Hypertension Renin-angiotensin-aldosterone System (RAAS) Inhibition Study
Condition: Hypertension
Intervention: Drug: Lisinopril, Atenolol
Outcome Measure: One type of blood pressure medication will better treat individuals with certain genetic backgrounds.
12 Recruiting Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm
Condition: Small Abdominal Aortic Aneurysm
Interventions: Drug: Beta-blocker-Atenolol 50mg, PO(peroral), Once daily;   Drug: Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily
Outcome Measure: Annual aneurysm growth of abdominal aortic aneurysm
13 Not yet recruiting Single Pill to Avert Cardiovascular Events
Condition: Cardiovascular Disease
Interventions: Drug: polipillV1;   Drug: polipillV2;   Drug: usual care
Outcome Measures: compliance with treatment;   changed in blood pressure;   changes in LDL-cholesterol levels;   the main reason for non compliance with treatment;   safety of poli pill measures by laboratorial tests;   combined outcome
14 Recruiting Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Cardiovascular Risk Assessment
Conditions: Essential Hypertension;   Cardiovascular Disease;   Stroke;   Chronic Kidney Disease
Interventions: Drug: Any antihypertensive medication alone or in combination;   Device: Ambulatory blood pressure monitoring
Outcome Measures: To evaluate the impact of circadian time of treatment in cardiovascular, cerebrovascular and renal risk assessment.;   To evaluate the influence of circadian time of treatment in BP control of hypertensive patients.;   To evaluate the prevalence of an altered (non-dipper) BP profile in patients with resistant hypertension as a function of the circadian time of treatment.;   To evaluate the influence of diabetes and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.;   To evaluate the influence of age and circadian time of treatment in the prevalence of an altered (non-dipper) BP profile.;   To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of white-coat hypertension.;   To evaluate, for all groups of interest, the prevalence and cardiovascular risk profile of masked hypertension.;   To evaluate, for all previous objectives, potential differences between men and women.;   To evaluate the impact of changes in ambulatory BP in cardiovascular, cerebrovascular and renal risk assessment.
15 Recruiting Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF
Condition: Atrial Fibrillation
Intervention: Other: Aggressive Blood Pressure control
Outcome Measures: Time to recurrent Atrial fibrillation;   Recurrence of AF at one year
16 Unknown  Heart Rate Reduction in Heart Failure
Condition: Heart Failure
Interventions: Drug: ivabradine;   Drug: Carvedilol/Ivabradine;   Drug: Carvedilol
Outcome Measures: Exercise tolerance assessed by 6 minute walking test;   Quality of life
17 Unknown  Anglo-Scandinavian Cardiac Outcomes Trial: Post Trial Follow-Up Study
Conditions: Hypertension;   Diabetes;   Death From Cardiovascular Disease;   Myocardial Infarction;   Stroke
Intervention:
Outcome Measures: Number of participants who have died from cardiovascular disease and the number who have suffered a non-fatal myocardial infarction (MI) and/or non-fatal stroke since the end of the ASCOT study;   Number of participants who have developed diabetes since the end of the ASCOT trial;   Number of participants who have undergone coronary/peripheral re-vascularisation procedures since the end of the ASCOT trial;   Number of participants who have required renal replacement therapy (dialysis or kidney transplant) since the end of the ASCOT trial;   Number of participants who have experienced a transient ischaemic attack since the end of the ASCOT trial
18 Recruiting The International Polycap Study 3 (TIPS-3)
Conditions: Cardiovascular Disease;   Fractures;   Cancers
Interventions: Drug: Polycap DS;   Drug: enteric coated aspirin;   Drug: cholecalciferol
Outcome Measures: Composite of major CVD (CV death, non-fatal stroke, non-fatal MI), plus heart failure, resuscitated cardiac arrest, or revascularization with evidence of ischemia in participants taking Polycap versus placebo;   Composite of CV events (CV death, MI or stroke) and cancer in participants taking aspirin versus placebo;   Risk of fractures in participants taking vitamin D versus placebo;   Composite of CV death, non-fatal stroke, and nonfatal MI in participants taking Polycap versus placebo;   Composite outcome of CV events and cancers after 10 years of follow up in participants taking aspirin versus placebo;   Composite outcome of CV events, fractures and cancers, and the risk of the falls at 10 years of follow up in participants taking vitamin D versus placebo
19 Recruiting Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Conditions: Atrial Fibrillation;   Arrhythmia
Interventions: Device: Left atrial ablation;   Drug: Rate or Rhythm Control Therapy
Outcome Measures: LA catheter ablation is superior to rate or rhythm control drug therapy for decreasing the incidence of the composite endpoint of total mortality, disabling stroke, serious bleeding, or cardiac arrest in patients warranting therapy for AF.;   LA catheter ablation is superior to rate or rhythm control drug therapy for reducing total mortality;   Total mortality or cardiovascular hospitalization;   Cardiovascular death;   Cardiovascular death or disabling stroke;   Arrhythmic death or cardiac arrest;   Heart failure death;   Freedom from recurrent AF;   Cardiovascular hospitalization;   Medical costs, resource utilization, and cost effectiveness;   Quality of Life;   Composite adverse events;   Left atrial size, morphology and function and its relationship to morbidity and mortality